Anzeige
Mehr »
Login
Montag, 15.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Im Fokus der Anleger: InnoCan Pharma vor entscheidendem Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QBSF | ISIN: US4131971040 | Ticker-Symbol:
NASDAQ
15.04.24
15:30 Uhr
29,660 US-Dollar
+0,170
+0,58 %
1-Jahres-Chart
HARMONY BIOSCIENCES HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
HARMONY BIOSCIENCES HOLDINGS INC 5-Tage-Chart

Aktuelle News zur HARMONY BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoHarmony Biosciences Holdings, Inc. - 8-K, Current Report2
DoHarmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist80PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and...
► Artikel lesen
03.04.Harmony Biosciences Initiates Global Phase 3 Registrational Trial (tempo Study) Of Pitolisant In Patients With Prader-willi Syndrome65PLYMOUTH MEETING, Pa., April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate...
► Artikel lesen
28.03.Evaluating Harmony Biosciences: Insights From 8 Financial Analysts1
19.03.Harmony Biosciences exec sells over $383k in stock1
28.02.Harmony Biosciences Holdings, Inc. - 10-K/A, Annual Report-
23.02.Earnings call: Harmony Biosciences reports 2023 growth driven by WAKIX1
22.02.Harmony Biosciences Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
22.02.Raymond James lifts Harmony Biosciences target on steady net patient adds2
22.02.Analyst Ratings For Harmony Biosciences1
22.02.Harmony Biosciences Holdings, Inc. - 10-K, Annual Report1
22.02.Harmony Biosciences Holdings, Inc. - 8-K, Current Report-
22.02.Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates146WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration (FDA)...
► Artikel lesen
22.02.Harmony Biosciences Non-GAAP EPS of $0.73 misses by $0.18, revenue of $168.4M in-line1
21.02.Harmony Biosciences Q4 2023 Earnings Preview1
21.02.Harmony Biosciences Sinks on FDA Nod-
21.02.Harmony Biosciences Receives FDA Priority Review For Wakix1
20.02.Harmony Biosciences Receives FDA's Orphan Drug Designation For Pitolisant In Prader-Willi Syndrome1
20.02.Harmony Biosciences Receives U.S. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-willi Syndrome179PLYMOUTH MEETING, Pa., Feb. 20, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation...
► Artikel lesen
08.01.Harmony Biosciences says Q4 preliminary net product revenue was about $168M3
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1